Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL

Read the full 202 word article

How to gain access

Continue reading with a
two-week free trial.